Key facts
- It has raised $3.3B; the latest was Accelerator/Incubator in May 2024.
- Notable investors include Tech Incubator Program for Startup, Schmidt (South Korea), ActnerLab, DSC Investment, Daewon Pharmaceutical Co — 8 tracked in total.
- 2 investment vehicles were formed to buy L-base shares in the last 12 months, reporting $3.7M sold to 32 investors, per SEC Form D filings.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for L-base
- ·The full record, as it builds
Funding rounds
No funding rounds for L-base are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Secondary demand: investment vehicles
from SEC Form D filingsIn the last 12 months, 2 investment vehicles were formed to buy L-base shares, reporting $3.7M sold to 32 investors across 2 sponsors. Most recent filing Nov 2025. Vehicles like these are how secondary buyers pool demand for a name; a rising count is a demand signal.
About L-base
Developer of an autophagy-targeted drug intended to overcome resistance to existing anticancer drugs. The company intends to develop therapeutic agents that can overcome resistance to targeted anticancer drugs using CAGE-derived peptides, helping patients reduce the possibility of side effects compared to the previous generation of chemotherapy.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2015
- Employees
- 9
- Website
- l-base.com/
- Ownership
- Privately Held (backing)
L-base doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in L-base shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on L-base in its N-PORT filings yet. We sweep new filings monthly.